-+ 0.00%
-+ 0.00%
-+ 0.00%

Press Release: Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Dow Jones·12/01/2025 13:30:00

Please log in to view news